Enrico Patrucco

Enrico Patrucco

Auto-generated profile, based on publicly available information

Enrico Patrucco

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino 10126, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in Cell
Verified
Journal Article
Closed access
EPEnrico Patrucco
Enrico Patrucco
ANAntonella Notte
Antonella Notte
LBLaura Barberis
Laura Barberis
GSGiulio Selvetella
Giulio Selvetella
AMAngelo Maffei
Angelo Maffei
EHEmilio Hirsch
Emilio Hirsch

18 October 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CACandace M. Adamo
Candace M. Adamo
DDDao-Fu Dai
Dao-Fu Dai
JPJustin M. Percival
Justin M. Percival
EMElina Minami
Elina Minami
MWMonte Willis
Monte Willis
JBJoseph A. Beavo
Joseph A. Beavo
Duchenne muscular dystrophy (DMD) is a progressive and fatal genetic disorder of muscle degeneration. Patients with DMD lack expression of the protein dystrophin as a result of mutations in the X-linked dystrophin gene. The loss of dystrophin leads to severe skeletal muscle pathologies as well as cardiomyopathy, which manifests as congestive heart failure and arrhythmias. Like humans, dystrophin-deficient mice ( mdx mice) show cardiac dysfunction as evidenced by a decrease in diastolic function followed by systolic dysfunction later in life. We have investigated whether sildenafil citrate (Viagra), a phosphodiesterase 5 (PDE5) inhibitor, can be used to ameliorate the age-related cardiac dysfunction present in the mdx mice. By using echocardiography, we show that chronic sildenafil treatment reduces functional deficits in the cardiac performance of aged mdx mice, with no effect on normal cardiac function in WT controls. More importantly, when sildenafil treatment was started after cardiomyopathy had developed, the established symptoms were rapidly reversed within a few days. It is recognized that PDE5 inhibitors can have cardioprotective effects in other models of cardiac damage, but the present study reports a prevention and reversal of pathological cardiac dysfunction as measured by functional analysis in a mouse model of DMD. Overall, the data suggest that PDE5 inhibitors may be a useful treatment for the cardiomyopathy affecting patients with DMD at early and late stages of the disease.

11 April 2005 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CVCarmine Vecchione
Carmine Vecchione
EPEnrico Patrucco
Enrico Patrucco
GMGennaro Marino
Gennaro Marino
LBLaura Barberis
Laura Barberis
RPRoberta Poulet
Roberta Poulet
GLGiuseppe Lembo
Giuseppe Lembo
Hypertension affects nearly 20% of the population in Western countries and strongly increases the risk for cardiovascular diseases. In the pathogenesis of hypertension, the vasoactive peptide of the renin-angiotensin system, angiotensin II and its G protein–coupled receptors (GPCRs), play a crucial role by eliciting reactive oxygen species (ROS) and mediating vessel contractility. Here we show that mice lacking the GPCR-activated phosphoinositide 3-kinase (PI3K)γ are protected from hypertension that is induced by administration of angiotensin II in vivo. PI3Kγ was found to play a role in angiotensin II–evoked smooth muscle contraction in two crucial, distinct signaling pathways. In response to angiotensin II, PI3Kγ was required for the activation of Rac and the subsequent triggering of ROS production. Conversely, PI3Kγ was necessary to activate protein kinase B/Akt, which, in turn, enhanced L-type Ca2+ channel–mediated extracellular Ca2+ entry. These data indicate that PI3Kγ is a key transducer of the intracellular signals that are evoked by angiotensin II and suggest that blocking PI3Kγ function might be exploited to improve therapeutic intervention on hypertension.

1 August 2010 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
EPEnrico Patrucco
Enrico Patrucco
MAMasami Shimizu Albergine
Masami Shimizu Albergine
LSLuis F. Santana
Luis F. Santana
JBJoseph A. Beavo
Joseph A. Beavo

1 April 2012 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
MSMasami Shimizu-Albergine
Masami Shimizu-Albergine
LTLi-Chun Lisa Tsai
Li-Chun Lisa Tsai
EPEnrico Patrucco
Enrico Patrucco
JBJoseph A. Beavo
Joseph A. Beavo
Phosphodiesterase (PDE) 8A and PDE8B are high-affinity, cAMP-specific phosphodiesterases that are highly expressed in Leydig cells. PDE8A is largely associated with mitochondria, whereas PDE8B is broadly distributed in the cytosol. We used a new, PDE8-selective inhibitor, PF-04957325, and genetically ablated PDE8A(−/−), PDE8B(−/−) and PDE8A(−/−)/B(−/−) mice to determine roles for these PDEs in the regulation of testosterone production. PF-04957325 treatment of WT Leydig cells or MA10 cells increased steroid production but had no effect in PDE8A (−/−)/B(−/−) double-knockout cells, confirming the selectivity of the drug. Moreover, under basal conditions, cotreatment with PF-04957325 plus rolipram, a PDE4-selective inhibitor, synergistically potentiated steroid production. These results suggest that the pool(s) of cAMP regulating androgen production are controlled by PDE8s working in conjunction with PDE4. Likewise, PDE8A (−/−)/B(−/−) cells had higher testosterone production than cells from either PDE8A(−/−) or PDE8B(−/−) mice, suggesting that both PDE8s work in concert to regulate steroid production. We further demonstrate that combined inhibition of PDE8s and PDE4 greatly increased PKA activity including phosphorylation of cholesterol-ester hydrolase (CEH)/hormone-sensitive lipase (HSL). CEH/HSL phosphorylation also was increased in PDE8A(−/−)/B(−/−) cells compared with WT cells. Finally, combined inhibition of PDE8s and PDE4 increased the expression of steroidogenic acute regulatory (StAR) protein. Together these findings suggest that both PDE8A and PDE8B play essential roles to maintain low cAMP levels, thereby suppressing resting steroidogenesis by keeping CEH/HSL inactive and StAR protein expression low. They also suggest that in order for PDE inhibitor therapy to be an effective stimulator of steroidogenesis, both PDE8 isozymes and PDE4 need to be simultaneously targeted.

30 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MNMarie-Julie Nokin
Marie-Julie Nokin
AMAlessia Mira
Alessia Mira
EPEnrico Patrucco
Enrico Patrucco
BRBiagio Ricciuti
Biagio Ricciuti
SCSophie Cousin
Sophie Cousin
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
Selective KRASG12C inhibitors have been developed to covalently lock the oncogene in the inactive GDP-bound state. Two of these molecules, sotorasib and adagrasib, are approved for the treatment of adult patients with KRASG12C-mutated previously treated advanced non-small cell lung cancer. Drug treatment imposes selective pressures leading to the outgrowth of drug-resistant variants. Mass sequencing from patients’ biopsies identified a number of acquired KRAS mutations -both in cis and in trans- in resistant tumors. We demonstrate here that disease progression in vivo can also occur due to adaptive mechanisms and increased KRAS-GTP loading. Using the preclinical tool tri-complex KRASG12C-selective covalent inhibitor, RMC-4998 (also known as RM-029), that targets the active GTP-bound (ON) state of the oncogene, we provide a proof-of-concept that the clinical stage KRASG12C(ON) inhibitor RMC-6291 alone or in combination with KRASG12C(OFF) drugs can be an alternative potential therapeutic strategy to circumvent resistance due to increased KRAS-GTP loading.